ArticleFrontiers in immunology2026
Surrogate virus neutralization test to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 spike RBD complex.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The viral pathogen SARS-CoV-2 caused a pandemic with detrimental effects across multiple domains. Mutations that gain transmission and infectability advantages have complicated virus prevention and mitigation. SARS-CoV-2 virus gains entry to human cells through the complex formed between the human Angiotensin Converting Enzyme 2 (hACE-2) and the viral spike protein. Neutralizing antibodies can block the binding of the spike protein to hACE-2, thereby neutralizing the virus. These antibodies are present in mucosal fluids and plasma. In this study, we demonstrate the deployment of a laboratory-developed surrogate virus neutralization test (sVNT) to assess the neutralizing activity of antibodies in saliva. Samples are collected from donors who completed the first two doses of the Pfizer vaccine, on average 36.6 weeks apart, and received the booster shot in September 2021. We analyzed the neutralizing activity of the saliva antibody against the spike receptor-binding domain (RBD) of the reference spike and the Omicron variant. The analytical sensitivity and specificity of the laboratory-developed sVNT are comparable to those of the FDA-approved sVNT. Vaccine-elicited saliva antibodies were able to block the binding of hACE-2 to the spike RBD of the reference strain. However, Omicron spike RBD abolished saliva neutralizing ability, implicating escape from mucosal immune defense. The experience we gained from assessing SARS-CoV-2 virus neutralization in saliva can be broadly applied to urgent needs against other pathogens, enabling us to quickly deploy a surrogate neutralization test to evaluate immune protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.